

Knobbe Martens Olson & Bear LLP

Intellectual Property Law

2040 Main Street
Fourteenth Floor
Irvine, CA 92614
Tel 949-760-0404
Fax 949-760-9502
www.kmob.com

Che S. Chereskin
Patent Agent

January 26, 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: Title: IMPLANTATION OF ENCAPSULATED BIOLOGICAL MATERIALS
FOR TREATING DISEASES
Letters Patent No. 7,427,415
Issued: September 23, 2008
Our Reference: NOVCEL.017A

Dear Sir:

Enclosed for filing is a Certificate of Correction in connection with the above-identified patent.

As some of the errors cited in the Certificate of Correction were incurred through the fault of the Applicant, the required payment of \$100 will be paid via the EFS Web. Please charge any additional fees to our Deposit Account No. 11-1410.

Respectfully submitted,

Knobbe, Martens, Olson & Bear, LLP



Che Swyden Chereskin, Ph.D.
Registration No. 41,466
Customer No. 20995

Enclosures

6533436
012609

San Diego
619-235-8550

San Francisco
415-954-4114

Los Angeles
310-551-3450

Riverside
951-781-9231

Seattle
206-405-2000

Washington, DC
202-640-6400

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,427,415
APPLICATION NO. : 10/684,859
ISSUE DATE : September 23, 2008
INVENTOR(S) : Scharp, et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 2, Column 2, Entry 5, (Foreign Patent Documents) "ES 210472T T3" should be changed to
--ES 2104727T T3--

Page 2, Column 2, Line 58, (Other Publications) "Procine Pancreatic" should be changed to --Porcine
Pancreatic--

Column 12, Line 51, "thoionine, riboflavin" should be changed to --thionine, riboflavin--

Column 13, Line 5, "omithine, histidine" should be changed to --ornithine, histidine--

Column 13, Line 58, "omithine, histidine" should be changed to --ornithine, histidine--

Column 15, Line 50, "at 285 days" should be changed to --at 285 days.--

Column 17, Line 67, "cells or tissue" should be changed to --cells or tissue.--

Column 21, Line 67, "loss of weight" should be changed to --loss of weight.--

Column 22, Line 2, "insulin granules" should be changed to --insulin granules.--

Column 29, Line 2, "omithine, histidine" should be changed to --ornithine, histidine--

Column 31, Line 25, "CaCl₂ and" should be changed to --CaCl₂ and--

Column 34, Line 14, "post-implantation" should be changed to --post-implantation.--

Column 41, Line 21, "cylosporinen administration" should be changed to --cyclosporine administration--

Column 51, Line 33, "and TBMX insulin" should be changed to --and IBMX insulin--

Column 54, Line 45, "encapsulated cells" should be changed to --encapsulated cell--

Column 54, Line 50, "weight of between" should be changed to --weight between--

Column 55, Line 13, "the polymerizable" should be changed to --the covalently polymerizable--

MAILING ADDRESS OF SENDER:

Che Swyden Chereskin, Ph.D.
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, California 92614

DOCKET NO. NOVCEL.017A

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 7,427,415
APPLICATION NO. : 10/684,859
ISSUE DATE : September 23, 2008
INVENTOR(S) : Scharp, et al.

Page 2 of 2

Column 55, Line 33, "omithine, histidine" should be changed to --ornithine, histidine--

Column 56, Line 8, "a polyethylene" should be changed to --a covalently linked polyethylene--

6533156
012609

MAILING ADDRESS OF SENDER:

Che Swyden Chereskin, Ph.D.
KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, California 92614

DOCKET NO. NOVCEL.017A